Journal Articles
CAR T cell therapy - quo vadis
Lead Editor:
-
Professor Michael Schmitt
,
Heidelberg University Hospital
,
Germany
CAR T cells have become a very powerful instrument in the armamentarium against CD19+ lymphoma and leukemia, as well as against BCMA+ multiple myeloma. This issue will update clinician with novel targets, CAR constructs and novel analysis of parameters for clinical responses to CAR T cell theray. Moreover, gene expression profiling of both malignant cells and CAR T cells can help us towards a better understanding of the success and failure in CAR T cell therapy.
Submission deadline:
22/07/2025
